PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry
Start Date
10/29/2025
Completion Date
12/31/2099
Summary
The design is an open-ended prospective observational (non-interventional) registry for subjects living with excess weight or obesity under the care of a qualified provider with documented experience treating patients with obesity
Detailed Description
The objective of the registry is to create a cohort of subjects living with excess weight or obesity to evaluate long-term real-world effectiveness and safety of standard of care treatments for obesity. Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to: characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of obesity, providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Biospecimen collection
Conditions
Locations
CorEvitas, LLC
Waltham, Massachusetts 02451
United States